SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Existing graphene biosensors are hand-made in academic labs using laborious
The new Protect and Expose fabrication process raises the state-of-the-art in graphene biosensors in three ways:
Using a unique material that's both biocompatible and conductive, commercial graphene biosensors have the distinct ability to connect directly to digital networks, opening the world of biochemistry to the possibilities of instantaneous analysis and machine learning for the first time.
"Graphene biosensors have the ability to revolutionize any field that requires mobile, digital biochemical measurements, including machine-learning integrated diagnostics, personal health monitoring, and field-deployable sample testing," says Nanomedical Diagnostics CTO, Brett Goldsmith. "The missing piece was standardized biosensors that offer consistent electrical properties at feasible prices. Our Protect and Expose process opens the door for commercial graphene biosensors to be used at a large scale in numerous industries."
Nanomedical Diagnostics manufactures Agile R100, a graphene biosensor assay platform for drug discovery that has been commercially available since late 2016. Since its launch, over 1,000 silicon foundry-fabricated biosensor chips have been sold for use with Agile R100.
About Nanomedical Diagnostics
Nanomedical Diagnostics ("Nanomed") is a life science company based in San Diego, CA. As the world's leading manufacturer and developer of next-generation graphene biosensors, Nanomed's mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.
SOURCE Nanomedical Diagnostics, Inc.
Subscribe to our Free Newsletters!